<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01203072</url>
  </required_header>
  <id_info>
    <org_study_id>DU176b-04</org_study_id>
    <nct_id>NCT01203072</nct_id>
  </id_info>
  <brief_title>A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty</brief_title>
  <official_title>A Phase 2b, Randomized, Double-Blind, Multi-Dose Efficacy, Safety and Dose-finding Study of the Oral Factor Xa Inhibitor DU-176b Compared With Placebo for Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty (STARS J-1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the efficacy, safety and dose-response relationship
      of DU-176b compared with placebo for the prevention of venous thromboembolism in patients
      after elective total knee arthroplasty.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Subjects With Venous Thromboembolism Events.</measure>
    <time_frame>2 weeks</time_frame>
    <description>The primary efficacy endpoint was the proportion of subjects who experienced at least one of the thromboembolic events listed below during the period from the start of study treatment to the venography at the end of study treatment.
Lower extremity DVT confirmed by bilateral venography at the end of study treatment
Definite diagnosis of symptomatic PE
Symptomatic DVT confirmed before the venography at the end of study treatment The objectives were to verify the non-inferiority of edoxaban to enoxaparin with regard to prevention of VTE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Major Bleeding or Clinically Relevant Non-major Bleeding</measure>
    <time_frame>2 weeks</time_frame>
    <description>Incidence of Major Bleeding or Clinically Relevant Non-major Bleeding. Related to the study drug</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">523</enrollment>
  <condition>Venous Thromboembolism</condition>
  <condition>Deep Vein Thrombosis</condition>
  <condition>Total Knee Arthroplasty</condition>
  <arm_group>
    <arm_group_label>DU-176b 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DU-176b 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DU-176b 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DU-176b 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DU-176b</intervention_name>
    <description>DU-176b 5mg tablets oral, once daily for 2 weeks</description>
    <arm_group_label>DU-176b 5 mg</arm_group_label>
    <other_name>edoxaban</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DU-176b</intervention_name>
    <description>DU-176b 15mg tablets, oral once daily for 2 weeks</description>
    <arm_group_label>DU-176b 15 mg</arm_group_label>
    <other_name>edoxaban</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DU-176b</intervention_name>
    <description>DU-176b 30 mg tablets, oral, once daily for 2 weeks</description>
    <arm_group_label>DU-176b 30 mg</arm_group_label>
    <other_name>edoxaban</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DU-176b</intervention_name>
    <description>DU-176b 60 mg tablets, oral, once daily for 2 weeks</description>
    <arm_group_label>DU-176b 60 mg</arm_group_label>
    <other_name>edoxaban</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo oral tablets, once daily for 2 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing unilateral total knee arthroplasty

        Exclusion Criteria:

          -  risks of hemorrhage

          -  thromboembolic risks

          -  weight less than 40 kg

          -  pregnant, suspect pregnancy, or subjects who want to become pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takeshi Fuji, Director</last_name>
    <role>Principal Investigator</role>
    <affiliation>Osaka Koseinekin Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2010</study_first_submitted>
  <study_first_submitted_qc>September 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2010</study_first_posted>
  <results_first_submitted>January 15, 2015</results_first_submitted>
  <results_first_submitted_qc>January 15, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 26, 2015</results_first_posted>
  <last_update_submitted>January 15, 2015</last_update_submitted>
  <last_update_submitted_qc>January 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prevention</keyword>
  <keyword>venous thromboembolism</keyword>
  <keyword>edoxaban</keyword>
  <keyword>factor Xa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edoxaban</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>DU-176b 5 mg</title>
          <description>DU-176b: DU-176b 5mg tablets oral, once daily for 2 weeks</description>
        </group>
        <group group_id="P2">
          <title>DU-176b 15 mg</title>
          <description>DU-176b: DU-176b 15mg tablets, oral once daily for 2 weeks</description>
        </group>
        <group group_id="P3">
          <title>DU-176b 30 mg</title>
          <description>DU-176b: DU-176b 30 mg tablets, oral, once daily for 2 weeks</description>
        </group>
        <group group_id="P4">
          <title>DU-176b 60 mg</title>
          <description>DU-176b: DU-176b 60 mg tablets, oral, once daily for 2 weeks</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Placebo: Matching placebo oral tablets, once daily for 2 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
                <participants group_id="P2" count="106"/>
                <participants group_id="P3" count="104"/>
                <participants group_id="P4" count="106"/>
                <participants group_id="P5" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="100"/>
                <participants group_id="P3" count="101"/>
                <participants group_id="P4" count="100"/>
                <participants group_id="P5" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DU-176b 5 mg</title>
          <description>DU-176b: DU-176b 5mg tablets oral, once daily for 2 weeks</description>
        </group>
        <group group_id="B2">
          <title>DU-176b 15 mg</title>
          <description>DU-176b: DU-176b 15mg tablets, oral once daily for 2 weeks</description>
        </group>
        <group group_id="B3">
          <title>DU-176b 30 mg</title>
          <description>DU-176b: DU-176b 30 mg tablets, oral, once daily for 2 weeks</description>
        </group>
        <group group_id="B4">
          <title>DU-176b 60 mg</title>
          <description>DU-176b: DU-176b 60 mg tablets, oral, once daily for 2 weeks</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Placebo: Matching placebo oral tablets, once daily for 2 weeks</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="88"/>
            <count group_id="B2" value="92"/>
            <count group_id="B3" value="88"/>
            <count group_id="B4" value="88"/>
            <count group_id="B5" value="89"/>
            <count group_id="B6" value="445"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.2" spread="7.7"/>
                    <measurement group_id="B2" value="71.7" spread="7.0"/>
                    <measurement group_id="B3" value="71.6" spread="8.1"/>
                    <measurement group_id="B4" value="72.1" spread="7.0"/>
                    <measurement group_id="B5" value="70.3" spread="6.5"/>
                    <measurement group_id="B6" value="71.2" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="69"/>
                    <measurement group_id="B5" value="68"/>
                    <measurement group_id="B6" value="347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="88"/>
                    <measurement group_id="B4" value="88"/>
                    <measurement group_id="B5" value="89"/>
                    <measurement group_id="B6" value="445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="88"/>
                    <measurement group_id="B4" value="88"/>
                    <measurement group_id="B5" value="89"/>
                    <measurement group_id="B6" value="445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Subjects With Venous Thromboembolism Events.</title>
        <description>The primary efficacy endpoint was the proportion of subjects who experienced at least one of the thromboembolic events listed below during the period from the start of study treatment to the venography at the end of study treatment.
Lower extremity DVT confirmed by bilateral venography at the end of study treatment
Definite diagnosis of symptomatic PE
Symptomatic DVT confirmed before the venography at the end of study treatment The objectives were to verify the non-inferiority of edoxaban to enoxaparin with regard to prevention of VTE</description>
        <time_frame>2 weeks</time_frame>
        <population>The FAS was defined as all subjects enrolled in the study, but excluded those who had significant GCP violations, who had not received any doses of the study drug, or those who did not develop symptomatic DVT or PE, but in whom venography was not appropriately performed.</population>
        <group_list>
          <group group_id="O1">
            <title>DU-176b 5 mg</title>
            <description>DU-176b: DU-176b 5mg tablets oral, once daily for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>DU-176b 15 mg</title>
            <description>DU-176b: DU-176b 15mg tablets, oral once daily for 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>DU-176b 30 mg</title>
            <description>DU-176b: DU-176b 30 mg tablets, oral, once daily for 2 weeks</description>
          </group>
          <group group_id="O4">
            <title>DU-176b 60 mg</title>
            <description>DU-176b: DU-176b 60 mg tablets, oral, once daily for 2 weeks</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo: Matching placebo oral tablets, once daily for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects With Venous Thromboembolism Events.</title>
          <description>The primary efficacy endpoint was the proportion of subjects who experienced at least one of the thromboembolic events listed below during the period from the start of study treatment to the venography at the end of study treatment.
Lower extremity DVT confirmed by bilateral venography at the end of study treatment
Definite diagnosis of symptomatic PE
Symptomatic DVT confirmed before the venography at the end of study treatment The objectives were to verify the non-inferiority of edoxaban to enoxaparin with regard to prevention of VTE</description>
          <population>The FAS was defined as all subjects enrolled in the study, but excluded those who had significant GCP violations, who had not received any doses of the study drug, or those who did not develop symptomatic DVT or PE, but in whom venography was not appropriately performed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="88"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.5" lower_limit="20.0" upper_limit="39.1"/>
                    <measurement group_id="O2" value="26.1" lower_limit="17.1" upper_limit="35.1"/>
                    <measurement group_id="O3" value="12.5" lower_limit="5.6" upper_limit="19.4"/>
                    <measurement group_id="O4" value="9.1" lower_limit="3.1" upper_limit="15.1"/>
                    <measurement group_id="O5" value="48.3" lower_limit="37.9" upper_limit="58.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>As the primary analysis, the dose-response relationship in the incidence of thromboembolic event was verified using the Cochran-Armitage test.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Significance level for Cochran-Armitage test and comparison using Shirley-Williams method was set at one-sided, 0.025. For other tests, significance level and confidence coefficient were set at two-sided, 0.05 and 0.95, respectively, unless specified</p_value_desc>
            <method>Cochran-Armitage</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Major Bleeding or Clinically Relevant Non-major Bleeding</title>
        <description>Incidence of Major Bleeding or Clinically Relevant Non-major Bleeding. Related to the study drug</description>
        <time_frame>2 weeks</time_frame>
        <population>Safety Analysis Set is defined as subjects secondarily enrolled in study, but excluded those with significant GCP violations, did not receive any doses of study drug, or had no safety data after start of study treatment. Subjects with significant GCP violations, but received at least one dose of study drug, safety data were assessed individually</population>
        <group_list>
          <group group_id="O1">
            <title>DU-176b 5 mg</title>
            <description>DU-176b: DU-176b 5mg tablets oral, once daily for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>DU-176b 15 mg</title>
            <description>DU-176b: DU-176b 15mg tablets, oral once daily for 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>DU-176b 30 mg</title>
            <description>DU-176b: DU-176b 30 mg tablets, oral, once daily for 2 weeks</description>
          </group>
          <group group_id="O4">
            <title>DU-176b 60 mg</title>
            <description>DU-176b: DU-176b 60 mg tablets, oral, once daily for 2 weeks</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo: Matching placebo oral tablets, once daily for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Major Bleeding or Clinically Relevant Non-major Bleeding</title>
          <description>Incidence of Major Bleeding or Clinically Relevant Non-major Bleeding. Related to the study drug</description>
          <population>Safety Analysis Set is defined as subjects secondarily enrolled in study, but excluded those with significant GCP violations, did not receive any doses of study drug, or had no safety data after start of study treatment. Subjects with significant GCP violations, but received at least one dose of study drug, safety data were assessed individually</population>
          <units>percentage of subjects with bleeds</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="106"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="106"/>
                <count group_id="O5" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.5" upper_limit="6.8"/>
                    <measurement group_id="O2" value="3.8" lower_limit="1.5" upper_limit="9.3"/>
                    <measurement group_id="O3" value="3.9" lower_limit="1.5" upper_limit="9.6"/>
                    <measurement group_id="O4" value="4.7" lower_limit="2.0" upper_limit="10.6"/>
                    <measurement group_id="O5" value="3.9" lower_limit="1.5" upper_limit="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>DU-176b 5 mg</title>
          <description>DU-176b: DU-176b 5mg tablets oral, once daily for 2 weeks</description>
        </group>
        <group group_id="E2">
          <title>DU-176b 15 mg</title>
          <description>DU-176b: DU-176b 15mg tablets, oral once daily for 2 weeks</description>
        </group>
        <group group_id="E3">
          <title>DU-176b 30 mg</title>
          <description>DU-176b: DU-176b 30 mg tablets, oral, once daily for 2 weeks</description>
        </group>
        <group group_id="E4">
          <title>DU-176b 60 mg</title>
          <description>DU-176b: DU-176b 60 mg tablets, oral, once daily for 2 weeks</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Placebo: Matching placebo oral tablets, once daily for 2 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA/JV.12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>vertigo positional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>compression fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>spinal compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>tibia fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>ligament rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA/JV.12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="78" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="78" subjects_at_risk="106"/>
                <counts group_id="E5" subjects_affected="67" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E5" events="8" subjects_affected="7" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="106"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="103"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E5" events="9" subjects_affected="8" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="103"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="106"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="103"/>
                <counts group_id="E4" events="17" subjects_affected="16" subjects_at_risk="106"/>
                <counts group_id="E5" events="12" subjects_affected="12" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>gamma glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="103"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="106"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="106"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>blood urine present</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="106"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="103"/>
                <counts group_id="E4" events="16" subjects_affected="15" subjects_at_risk="106"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>haemoglobin decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>platelet count increased</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="103"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="106"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="103"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>blood alkaline phosphate increased</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="103"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="106"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="103"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="106"/>
                <counts group_id="E5" events="9" subjects_affected="9" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="103"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>haematuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>dermatitis contact</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>heamorrhage subcutaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>pruritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>wound haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI shall not publish the results of the Study at any time without the prior written approval of Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kei Ibusuki, Associate Director</name_or_title>
      <organization>Daiichi Sankyo.,LTD</organization>
      <phone>81-90-2732-9505</phone>
      <email>ibusuki.kei.tx@daiichisankyo.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

